SILO PHARMA, INC. Management Fee Payable
SILO PHARMA, INC. (SILO) had Management Fee Payable of EUR 433.88 thousand as of 2021-12-31, per its 10-K filed 2022-03-28.
Discontinued › Balance Sheet › Liabilities
us-gaap:ManagementFeePayable · last filed 2022-03-28
- 2021-12-31: Management Fee Payable 433.88K EUR.
- 2021-09-30: Management Fee Payable 433.88K EUR.
EUR
| Period end | Management Fee Payable |
|---|---|
| 2021-12-31 | 433.88K EUR 10-K · filed 2022-03-28 |
| 2021-09-30 | 433.88K EUR 10-Q · filed 2021-11-10 |
USD
| Period end | Management Fee Payable |
|---|---|
| 2021-12-31 | $507.60K 10-K · filed 2022-03-28 |
| 2021-09-30 | $507.60K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |